Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: This study was published in December, 2007 in the Journal of Environmental Health. It was co-authored by Anne LaGrange Loving and John Perz. The authors collected 76 lemon slices from 21 restaurants on 43 visits in Patterson, New Jersey. They swabbed both the lemon slice and the glass on which the slice had been placed and immediately after the glass had been brought to them. The result was that they found contamination on both the flesh and the rind of most of the lemon wedges, although they did not research how it got there. Some of it could have arrived with the fruit from the field, some of it could have been through contamination from the hands of employees. Some of it could have been from contaminated work surfaces. The U.S. Food and Drug Administration conducted a study in 2004 of both fast food and full service restaurants. The conclusion was that there was poor personal hygiene on the part of employees at 31 percent of the fast food restaurants and more than 41 percent of the full service restaurants. Comments Claim: The forwarded email appears to be an article featuring the findings of microbiologist Anne LaGrange Loving who found that two-thirds of the lemons tested from 21 restaurants were contaminated with bacteria when added as slices to beverages.

Output: Contaminated Lemon Slices in Restaurants

Input: Consider Input: Paragraph: The release makes no mention of the cost of the drug in question, Tenofovir. A web search found that the cost for a month's supply of the antiviral drug averages just over $1,000. For some patients, that cost may be prohibitive. The cost is an issue of particular concern for developing countries, but it is also true that the price may be much lower for them than in the United States. Many pharmaceutical companies offer their drugs at steeply discounted rates in poorer countries to expand access to life-saving medicines. The release clearly says that 68 percent of women receiving the drug reduced their viral load while only 2 percent of the women in the control group had that success. It also says that the transmission of hepatitis B from mother to newborn dropped from 18 percent to 5 percent, an important clinical outcome. The release includes a discussion of harms. It states that "tenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea." It also says that researchers "found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth." Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment. The release provides a good overview of the randomized, placebo-controlled trial which was undertaken to gauge the efficacy of the drug in both reducing the viral load of hepatitis-B-positive mothers and reducing the rate of transmission of the disease from mother to newborn. It offers solid, numerical evidence of both outcomes. It describes the number of patients (200 pregnant women), defined what constituted a "high" viral load, and described the approximate length of treatment. It did omit a mention of whether the trial was blinded. This release does not commit disease mongering. The release notes that the research is funded by Gilead Sciences. It should also have mentioned that a corresponding author disclosed speaking and advising fees from Gilead, according to the published study. The release is comparing the use of an antiviral drug given to pregnant women versus the normal procedure of giving both a vaccine and immune globulin. The release doesn't mention that tenofovir (marketed as Viread), the drug being tested, is already an FDA approved drug so many readers may not know that it's available. It was approved by the FDA in 2001 for HIV and in 2008 for chronic hepatitis B. The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant: "Based on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants." While the drug itself isn't novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach. This release does not use any unjustifiable language. Claim: Antiviral Treatment During Pregnancy Reduces Mother-to-Child Transmission of Hepatitis B

Output: This news release describes a clinical trial testing whether an antiviral drug given to pregnant women in their third trimester reduces their hepatitis B viral load. The study also examined whether the drug limits the transmission of the virus from mother to baby. The answers to both questions are yes, suggesting a new strategy for dealing with the spread of this disease. The release does a good job describing harms, quantifying benefits and describing the study protocol. Because the cost of hepatitis drugs has been widely debated for the past few years, a mention of the drug's cost would have made the release stronger. Almost 240 million people are infected with hepatitis B virus and about 780,000 die each year from the disease, according to the World Health Organization. The hepatitis B virus infects the liver and while many recover with treatment, it can become a chronic infection. Babies and young children infected with the virus are more likely to develop chronic hepatitis B. If administering a drug to infected mothers reduces the proportion of newborns getting the disease, it would be a considerable improvement in public health.

Input: Consider Input: Paragraph: Ebola has left those living in the country's east weary and fearful, and, just as they were preparing to declare an end to the outbreak, a new case popped up. Now, they will now have to manage both threats at once. The new virus has overwhelmed some of the world's best hospital systems in Europe and ripped through communities in New York. In Congo, it could spread unchecked in a country that has endured decades of conflict, where corruption has left the the population largely impoverished despite mineral wealth, and where mistrust of authority is so entrenched that health workers have been killed during the Ebola outbreak. It's also unclear how forthcoming international support will be at a time when the whole world is battling the coronavirus. "It all feels like one big storm," said Martine Milonde, a Congolese community mobilizer who works with the aid group World Vision in Beni, which has been the epicenter of the Ebola outbreak. "Truly, this is a crisis within a crisis within a crisis. The community suffers from insecurity, and suffered under Ebola, and now may have to face COVID-19." In early March, an Ebola patient whom many hoped would be the last was discharged, and the outbreak was supposed to be officially declared over Sunday. But the World Health Organization on Friday announced a new case in Beni. The outbreak has claimed more than 2,260 lives since August 2018 the second largest the world has ever seen, after the 2014-2016 outbreak in West Africa. Still, there is some hope: Many of the tools used to fight Ebola hand-washing and social distancing chief among them are also key to combating the coronavirus. In Beni, which has reported two cases of the new coronavirus, "the communities here hold onto some hope that they are going to overcome this pandemic the way they had been working to overcome Ebola," said Milonde. "They are counting on the caution, vigilance and hygiene practices that they have been performing to save their families." Community advocates in Beni who walk around with megaphones to talk about Ebola have started to include warnings about the coronavirus. Messages explaining COVID-19, the disease caused by the virus, and where to go if sick are being spread on radio stations, through text message blasts and by religious leaders. Schools, churches and mosques are already armed with hand-washing kits. Beni's mayor, Nyonyi Bwanakawa, says many of the measures will be familiar but the recommendations to stay home are more stringent than what is required for Ebola, and officials are prepared to take "dramatic measures" if people resist. Unlike Ebola, which kills about half of the people it infects, the new coronavirus causes mostly mild or moderate symptoms in about 80% of people. Spreading Ebola typically requires an exchange of bodily fluids, and people have often been infected when caring for loved ones or mourning in traditional funerals that involve close contact with the body. In contrast, the new coronavirus is far more contagious and mostly spread by people coughing or sneezing, including those with only mild flu-like symptoms. That means the task of controlling the virus' spread in Congo will be massive: The government has only limited control in parts of the vast country, there are also some dense population centers with poor sanitation and infrastructure, and the country's mineral-rich east is beset by violence from various armed groups. Dr. Michel Yao, program manager for emergency response at the WHO's Africa office, said implementing robust testing and contact tracing will be key. But getting the community fully involved in fighting the disease might be even more important. That means not just speaking at communities, "but giving them responsibility and roles to play." Initially, efforts to control Ebola were met with resistance, one of the major contributors to its spread. Amid the insecurity in the country's east, superstitions arose, and some clinics to treat Ebola patients were attacked and health workers killed. The capital, Kinshasa, a tightly packed city of 14 million located on the country's western border, remains another major worry, said Yao, who is based at WHO's African headquarters in the neighboring Republic of Congo. "If it reaches this place, it would be a big disaster," he said. "Africa is only partly ready," said Yao. "If we stick to sporadic cases, this can be managed." But many more developed countries have seen cases surge, and a sizable outbreak in Congo could easily overwhelm its hospital system. Advanced equipment to deal with severe respiratory illness, which the coronavirus can cause, is lacking: The Health Ministry says there are about 65 ventilators all in Kinshasa and 20 more on order for a country of more than 80 million people. There have been 215 confirmed cases of the new coronavirus in Congo, with 20 deaths, the ministry said Friday. And health workers will also need to find a way to continue to treat people infected with the many other diseases that regularly torment the population. Over the past year, for instance, a measles outbreak killed more than 6,000 people in Congo. In addition, because donor countries are themselves dealing with outbreaks, help from abroad could be less forthcoming. The key, Yao said, is training more people locally to care for the ill. The challenge will be rallying again after many months of trying to contain Ebola. "The job wasn't yet finished, and we have to deal with another emergency," Yao said. Katungo Methya, 53, who volunteers for the Red Cross in Beni, expressed a weariness many feel. "It's so upsetting to have this second disease. We lost so many people through Ebola, a lot of deaths, now corona," she said. "Everyone is really afraid." ___ Petesch reported from Dakar, Senegal. AP medical writer Maria Cheng in London contributed from London. Claim: Congo, weary from Ebola, must also battle the coronavirus.
Output: Congo has been battling an Ebola outbreak that has killed thousands of people for more than 18 months, and now it must also face a new scourge: the coronavirus pandemic.